141 citations,
September 2016 in “European Journal of Dermatology” Taxane chemotherapy can cause skin, hair, and nail side effects, which are often under-reported and can affect patient quality of life.
131 citations,
October 2004 in “Clinical Cancer Research” Tempol is safe and may prevent hair loss from brain radiotherapy.
125 citations,
May 2019 in “Phytomedicine” Cepharanthine is a well-tolerated drug with multiple medical uses, including anti-inflammatory and anti-cancer properties.
123 citations,
September 1987 in “JAMA” IL-2 treatment causes skin eruptions and other reversible side effects, and may play a role in psoriasis.
93 citations,
February 2009 in “Annals of the New York Academy of Sciences” 5α‐reductase isozymes are crucial for prostate development and health, and targeting them can help prevent and treat prostate issues.
88 citations,
February 2008 in “Journal of Medicinal Chemistry” Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.
81 citations,
February 2000 in “Anti-cancer drugs” Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.
47 citations,
September 2016 in “Reviews in endocrine and metabolic disorders” The skin's ability to produce hormones is linked to various skin conditions, and better understanding this process could lead to new treatments.
47 citations,
November 2012 in “Expert Opinion on Therapeutic Patents” The document concludes that research on sulfatase inhibitors should continue due to their potential in treating various diseases, despite some clinical trial failures.
46 citations,
February 2012 in “Oncology Reports” Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.
38 citations,
December 2009 in “Therapeutic Advances in Medical Oncology” The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
37 citations,
June 2011 in “Journal of The American Academy of Dermatology” Loss of sebaceous glands and inflammation may contribute to the development of scarring alopecia.
35 citations,
January 2012 in “The Journal of Sexual Medicine” Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.
35 citations,
May 2008 in “Journal of Clinical Oncology” A cancer patient died from a severe skin reaction after taking the drug cetuximab.
34 citations,
March 2012 in “Circulation” Bridging anticoagulation may raise post-surgery bleeding risks.
34 citations,
December 2009 in “The International Journal of Developmental Biology” Too much thymosin beta4 causes weird teeth and more hair growth in mice.
32 citations,
February 2017 in “Oncotarget” Cellular senescence has both cancer-blocking and cancer-promoting effects, and targeting senescent cells may improve health and lifespan.
28 citations,
July 2017 in “Expert Review of Anticancer Therapy” Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
25 citations,
January 2021 in “Journal of drugs in dermatology” Sonidegib and vismodegib are similarly effective for advanced basal cell carcinoma, but sonidegib might have a slightly better safety profile.
24 citations,
April 2017 in “Oncology Reports” The hair keratin gene KRT81 is found in both normal and breast cancer cells and helps them invade surrounding tissues.
23 citations,
January 2014 in “International Journal of Biological Sciences” African American men with prostate cancer have more androgen receptor mutations, which may lead to more aggressive cancer compared to Caucasian American men.
21 citations,
May 1989 in “Advanced Drug Delivery Reviews” Liposomes show promise in cancer treatment by delivering drugs with less toxicity and improved effectiveness.
19 citations,
October 2011 in “Clinics in Dermatology” New chemotherapy drugs cause skin side effects, but treatments like minocycline and tetracycline can help reduce them.
18 citations,
July 2008 in “Current Oncology Reports” EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
18 citations,
December 1996 in “Seminars in Cutaneous Medicine and Surgery” Chemotherapy and cytokine therapy can cause various skin reactions, including hair loss and hypersensitivity.
17 citations,
February 2012 in “Cutaneous and Ocular Toxicology” Patients with chronic renal failure on hemodialysis often have skin problems like dry skin, itching, and nail changes.
16 citations,
March 2018 in “Seminars in Oncology” The document concludes that pregnancy and cancer share immune evasion tactics, but more research is needed before using checkpoint blockade immunotherapy in pregnant cancer patients to avoid harm to the placenta.
16 citations,
March 2015 in “Clinical Cancer Research” The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.
16 citations,
January 2003 in “Nuclear Receptor Signaling” Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.
15 citations,
March 2021 in “Journal of clinical medicine” Biologic treatments for Crohn's disease and ulcerative colitis can cause skin problems, and doctors should adjust treatment if these occur.